| P2093 | author name string | Pierre Chue | |
| | James Chue | |
| P2860 | cites work | Family history of psychiatric illness as a risk factor for schizoaffective disorder: a Danish register-based cohort study. | Q50542645 |
| | Treatment patterns for schizoaffective disorder and schizophrenia among Medicaid patients. | Q51872875 |
| | Treatment adherence in bipolar I and schizoaffective disorder, bipolar type | Q57612378 |
| | Psychopathological and social status of patients with affective, schizophrenic and schizoaffective disorders after long-term course | Q68668029 |
| | Distinction of schizoaffective from schizophrenic profile. Independent validation | Q69149744 |
| | Ten-year outcome: patients with schizoaffective disorders, schizophrenia, affective disorders and mood-incongruent psychotic symptoms | Q73144743 |
| | Frequency of schizoaffective disorder in an International patient population with psychotic disorders using the Mini-International Neuropsychiatric Interview | Q83064995 |
| | Are oxidative stress markers useful to distinguish schizoaffective disorder from schizophrenia and bipolar disorder? | Q87937371 |
| | Quality of life of people with schizophrenia, bipolar disorder and other psychotic disorders | Q37805287 |
| | Differential diagnosis and therapeutic management of schizoaffective disorder. | Q37823352 |
| | What we know and what we don't know about the treatment of schizoaffective disorder. | Q37874779 |
| | Oral paliperidone: a review of its use in the management of schizoaffective disorder | Q37885980 |
| | Clinical pharmacology of paliperidone palmitate a parenteral long-acting formulation for the treatment of schizophrenia | Q37948880 |
| | A review of paliperidone palmitate | Q38067137 |
| | The pharmacology and formulation of paliperidone extended release | Q38067139 |
| | Antipsychotic switching in schizoaffective disorder: A systematic review | Q38370545 |
| | A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder | Q38373315 |
| | Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response | Q38381132 |
| | Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder | Q38418177 |
| | Early non-adherence to medication and other risk factors for rehospitalization in schizophrenia and schizoaffective disorder | Q40002064 |
| | Signalling profile differences: paliperidone versus risperidone | Q41906281 |
| | Efficacy and safety of risperidone in the treatment of schizoaffective disorder: initial results from a large, multicenter surveillance study. Group for the Study of Risperidone in Affective Disorders (GSRAD). | Q42659869 |
| | Paliperidone extended-release in schizoaffective disorder: a randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers | Q42918752 |
| | Psychometric evaluation of the Medication Satisfaction Questionnaire (MSQ) to assess satisfaction with antipsychotic medication among schizophrenia patients | Q43155262 |
| | Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. | Q43230436 |
| | Quality of life in bipolar and schizoaffective disorder--a naturalistic approach | Q44135231 |
| | Transcultural differences in suicide attempters: analysis on a high-risk population of patients with schizophrenia or schizoaffective disorder | Q46200521 |
| | Long-acting risperidone in stable patients with schizoaffective disorder | Q46689239 |
| | Heavy utilization of inpatient and outpatient services in a public mental health service | Q47190695 |
| | Is schizoaffective disorder still a neglected condition in the scientific literature? | Q48606602 |
| | Rates and clinical correlates of treatment non-adherence in schizoaffective bipolar patients. | Q48735347 |
| | Developing an individualized treatment plan for patients with schizoaffective disorder: from pharmacotherapy to psychoeducation | Q48930896 |
| | Informing DSM-5: biological boundaries between bipolar I disorder, schizoaffective disorder, and schizophrenia | Q21245294 |
| | Suicide and schizophrenia: a systematic review of rates and risk factors | Q22241794 |
| | Social function in schizophrenia and schizoaffective disorder: associations with personality, symptoms and neurocognition | Q24792471 |
| | Does schizoaffective disorder really exist? A systematic review of the studies that compared schizoaffective disorder with schizophrenia or mood disorders | Q33295092 |
| | Schizoaffective disorder: role of atypical antipsychotics | Q33586352 |
| | An overview of the treatment of schizoaffective disorder | Q33587567 |
| | Assessing medication adherence and healthcare utilization and cost patterns among hospital-discharged patients with schizoaffective disorder. | Q33633758 |
| | Treatment of schizoaffective disorder and schizophrenia with mood symptoms | Q33713157 |
| | Differing correlates for suicide attempts among patients with schizophrenia or schizoaffective disorder in India and USA. | Q33843001 |
| | Life expectancy at birth for people with serious mental illness and other major disorders from a secondary mental health care case register in London | Q33911053 |
| | Alterations in somatostatin mRNA expression in the dorsolateral prefrontal cortex of subjects with schizophrenia or schizoaffective disorder | Q33922855 |
| | Role of paliperidone extended-release in treatment of schizoaffective disorder | Q34184199 |
| | Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study | Q34293899 |
| | Schizoaffective Disorder in the DSM-5. | Q34346693 |
| | The schizoaffective disorder diagnosis: a conundrum in the clinical setting | Q34391481 |
| | Carving chaos: genetics and the classification of mood and psychotic syndromes | Q34512018 |
| | Pharmacologic treatment of hospitalized patients with schizoaffective disorder | Q34520212 |
| | Lower glutamic acid decarboxylase 65-kDa isoform messenger RNA and protein levels in the prefrontal cortex in schizoaffective disorder but not schizophrenia | Q34587796 |
| | Lifetime prevalence of psychotic and bipolar I disorders in a general population | Q34596831 |
| | Schizoaffective disorder: diagnostic issues and future recommendations | Q34736821 |
| | Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness | Q35073474 |
| | Impact of switching to long-acting injectable antipsychotics on health services use in the treatment of schizophrenia | Q35566090 |
| | Combination of "atypical" antipsychotic medication in the management of treatment-resistant schizophrenia and schizoaffective disorder | Q35612449 |
| | Comparative Pharmacology of Risperidone and Paliperidone | Q35807345 |
| | A Systemic Review and Experts' Consensus for Long-acting Injectable Antipsychotics in Bipolar Disorder | Q35965634 |
| | Diagnostic shifts during the decade following first admission for psychosis | Q36660424 |
| | Insight into illness: impact on diagnosis and outcome of nonaffective psychosis | Q37225928 |
| | McLean-Harvard International First-Episode Project: two-year stability of DSM-IV diagnoses in 500 first-episode psychotic disorder patients | Q37268306 |
| | Treatment of schizoaffective disorder | Q37285395 |
| | NPY mRNA expression in the prefrontal cortex: Selective reduction in the superficial white matter of subjects with schizoaffective disorder | Q37438863 |
| | Cognitive functioning in schizophrenia, schizoaffective disorder and affective psychoses: meta-analytic study | Q37641661 |
| | Paliperidone extended-release: a review of efficacy and tolerability in schizophrenia, schizoaffective disorder and bipolar mania | Q37790388 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | schizoaffective disorder | Q834047 |
| P304 | page(s) | 109-16 | |
| P577 | publication date | 2016-01-01 | |
| P1433 | published in | Therapeutics and Clinical Risk Management | Q15766913 |
| P1476 | title | A critical appraisal of paliperidone long-acting injection in the treatment of schizoaffective disorder | |
| P478 | volume | 12 | |